A Distinct Evaluation On ‘Next Generation Antibody Therapeutics Market’, by Persistence Market Research, Offers In-Intensity Insights On Contemporary Developments Influencing The Marketplace Growth. Key Records Concerning Market Length, Marketplace Proportion, Facts, Application, And Revenue Are Compiled Within The Studies Look At To Carry Key Insights And Forecasts Years. In Addition, This Studies Gives An In Depth Aggressive Evaluation With Records At The Differential Product And Business Techniques Of Key Players Within The Next Generation Antibody Therapeutics Market.
According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.
Next-generation antibody therapeutics refers to improved antibody therapeutics with enhanced efficiency, greater safety, and improved delivery. Advancements in monoclonal antibody technologies have led to the development of next-generation therapeutic antibodies with reduced functional size, greater bifunctional properties, and low immunogenicity. Next-generation antibody-based therapeutics enhances existing properties of therapeutic antibodies for the treatment of various medical conditions such as cancer, infectious diseases, and autoimmune diseases.
|To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/3713|
Globally, the next-generation antibody therapeutics market is witnessing significant growth due to technological advancements in antibody therapeutics and increasing the prevalence of chronic diseases. In addition, rising healthcare expenditure and growing R & D activities are driving the growth of the next-generation antibody therapeutics market. However, stringent regulatory requirements and long approval time for new drug restrains the growth of the market. Similarly, high costs of next-generation antibody therapeutics is a major concern for the market.
North America is the largest market for next-generation antibody therapeutics. This is mainly due to increasing prevalence of chronic diseases and increasing healthcare spending in the region. The North America next-generation antibody therapeutics market is projected to be valued at US$ 1,104.4 Mn by the end of 2015 and is expected to account for US$ 3,691.8 Mn by 2022 at a CAGR of 14.5%. On the basis of technology, biosimilar antibody products are the fastest growing segment. On the basis of therapeutic application, oncology is the largest segment in next-generation antibody therapeutics market.
|For Critical Insights on Market, Request For Methodology of Report @ https://www.persistencemarketresearch.com/methodology/3713|
Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics. Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
The next-generation antibody therapeutics market is segmented as follows:
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies (BsAbs)
- Fc Engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
By Therapeutic Application
- Autoimmune/Inflammatory Diseases
- North America
- Rest of the World (RoW)